Our press releases

News Our press releases

uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award

in portfolio news

uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it has been recognized by Frost & Sullivan as a 2017 Manufacturing Leadership Awards winner for outstanding achievement in Engineering & Production Technology Leadership related to its Lexington, Massachusetts gene therapy manufacturing facility.

uniQure's Lexington-based facility is one of the largest, most versatile gene therapy manufacturing facilities in the world. Over the past four years, uniQure has invested more than $25 million in designing, constructing and equipping its 55,000 square foot facility with state-of-the-art laboratories and commercial-scale production capabilities. The facility offers 500-liter capacity with the ability to expand to up to 2,000 liters when needed.

"The innovative design of our facility, which incorporated 3D modeling and single-use components, required substantially less upfront capital expenditures and enables us to operate at significantly lower costs compared to other production systems," stated Lance Weed, vice president of operations for uniQure. "Our use of disposable components in our manufacturing process reduces the need for maintenance and testing, lowers the risk of contamination, enables rapid product changeovers, and requires substantially less personnel to operate."